TB-500
NOT FDA APPROVEDHealing & recovery peptide
Also known as: Thymosin Beta-4 fragment, TB4
Not FDA approved. Sold as a research chemical, labelled not for human consumption.
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- Registered human trials. 1 registered study on ClinicalTrials.gov, most advanced Phase 2
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: the parent protein Thymosin Beta-4 has been in some human trials (for example dry-eye and wounds). The 'TB-500' fragment sold online is not the same molecule and has no human efficacy data. Recovery claims are unproven.
What it is
A synthetic fragment related to Thymosin Beta-4, a protein involved in cell migration and repair. Proposed to support tissue regeneration and reduce inflammation.
What the research says
Animal and cell studies suggest a role in repair. No robust human trials for the injectable fragment sold online.
Reported by athletes and users. No controlled data.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing TB-500 in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
Elimination of theobromine metabolites in healthy adults.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where TB-500 is the intervention being tested.
FDA recalls & enforcement
TB-500 has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- No long-term human safety data.
- Banned by WADA for athletes in and out of competition.
- Gray-market purity varies widely.
Doses reported in studies & protocols
Community protocols vary widely (often cited in the low milligram range per week). No established clinical dose. This is not a recommendation.
Purity reality
Purity and actual peptide content vary a lot between vendors. A third-party COA is the only real check.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.